Emerging Therapeutics in COPD: Mapping Innovation to Treatable Traits
Lung · 2025-12 · 203 (1)
DOI: 10.1007/s00408-025-00844-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Lung, online erschienen am 03.09.2025. Verfasst von Mario Cazzola und 4 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. mario.cazzola@uniroma2.it. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Precision Medicine, Anti-Inflammatory Agents, Bronchodilator Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma Tor Vergata.
Themen: COPD
Abstract (Originalsprache)
Chronic Obstructive Pulmonary Disease (COPD) is a complex, heterogeneous condition characterized by diverse clinical phenotypes and underlying pathobiological mechanisms. Traditional “one-size-fits-all” management strategies have limited effectiveness in addressing this heterogeneity. The Treatable Traits (TTs) approach represents a precision medicine paradigm that targets specific, identifiable, and modifiable traits in individual patients, regardless of diagnostic labels. This paper explores the alignment between the TTs framework and emerging pharmacological therapies, with a particular focus on anti-inflammatory agents and bronchodilators currently under investigation. Each drug category is mapped to relevant TTs, such as eosinophilic or neutrophilic inflammation, corticosteroid resistance, chronic bronchitis, and frequent exacerbations. This review highlights the importance of biomarker-driven phenotyping and real-world data in designing TT-based clinical trials. It emphasizes challenges such as trait instability over time, comorbidity clustering, and trial design heterogeneity. Moreover, we advocate for incorporating digital health tools, long-term follow-up, and cost-effectiveness analyses to ensure translational relevance. In conclusion, integrating emerging therapies with the TTs approach holds substantial promise for personalizing COPD management, improving outcomes, and facilitating targeted drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy. mario.cazzola@uniroma2.it.
- College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia.
- Department of Respiratory and Sleep Medicine, John Hunter Hospital, New Lambton Heights, NSW, Australia.
- Clinic of Respiratory Medicine, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Rome, Italy.
- Unit of Pharmacology, Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', Naples, Italy.
Förderung
- Università degli Studi di Roma Tor Vergata
Zitieren
APA
Cazzola, M., McDonald, V. M., Stolz, D., Rogliani, P., & Matera, M. G. (2025). Emerging Therapeutics in COPD: Mapping Innovation to Treatable Traits. Lung, 203(1). https://doi.org/10.1007/s00408-025-00844-0
Vancouver
Cazzola M, McDonald VM, Stolz D, Rogliani P, Matera MG. Emerging Therapeutics in COPD: Mapping Innovation to Treatable Traits. Lung. 2025;203(1). doi:10.1007/s00408-025-00844-0
BibTeX
@article{Cazzola2025,
author = {Cazzola, Mario and McDonald, Vanessa M and Stolz, Daiana and Rogliani, Paola and Matera, Maria Gabriella},
title = {Emerging Therapeutics in COPD: Mapping Innovation to Treatable Traits},
journal = {Lung},
year = {2025},
volume = {203},
number = {1},
doi = {10.1007/s00408-025-00844-0}
}
EUVIMED